Journal of the Formosan Medical Association = Taiwan yi zhi · 2026
Cardiovascular risk profiles among patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Taiwan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsai Chi-Ning, Wang Yi-Chih, Tsai Yi-Te, Chang Sheng-Nan
Аннотация
BACKGROUND: While cardiovascular comorbidities are well described in multiple sclerosis (MS), they remain poorly characterized in neuromyelitis optica spectrum disorder (NMOSD). We aimed to identify cardiovascular risk associations in a Taiwanese cohort and compare risk profiles between MS and NMOSD.
METHODS: A retrospective analysis was conducted using rigorously validated clinical records from a tertiary medical center in Taiwan (2016-2023). Patients diagnosed with MS (n = 48) or NMOSD (n = 17) were included. Standardized prevalence ratios (SPRs) were calculated to compare comorbidity rates with the general population. Pharmacological treatment patterns were analyzed to assess disease management burden.
RESULTS: MS patients exhibited a higher incidence of established cardiovascular events compared to NMOSD patients. SPR analysis revealed a significantly lower prevalence of dyslipidemia in both MS (SPR 0.45, 95% CI 0.18-0.93) and NMOSD (SPR 0.16, 95% CI 0.004-0.89) compared with the general population. However, dyslipidemia remained the strongest predictor of cardiovascular events in MS (p < 0.001). In NMOSD, despite a hypertension prevalence comparable to the general population (SPR 0.92), patients had significantly higher usage of angiotensin II receptor blockers (35.3% vs. 12.8%, p = 0.041) and direct oral anticoagulants (11.8% vs. 0%, p = 0.016), coinciding with universal corticosteroid use (100%).
CONCLUSION: Taiwanese MS and NMOSD patients exhibit distinct cardiovascular phenotypes. MS is characterized by a "lipid paradox" where dyslipidemia, though less prevalent, serves as a high-potency risk trigger. In NMOSD, cardiovascular risk is treatment-related and masked by high medication burden. Comprehensive risk assessment must prioritize these specific metabolic and iatrogenic factors.
METHODS: A retrospective analysis was conducted using rigorously validated clinical records from a tertiary medical center in Taiwan (2016-2023). Patients diagnosed with MS (n = 48) or NMOSD (n = 17) were included. Standardized prevalence ratios (SPRs) were calculated to compare comorbidity rates with the general population. Pharmacological treatment patterns were analyzed to assess disease management burden.
RESULTS: MS patients exhibited a higher incidence of established cardiovascular events compared to NMOSD patients. SPR analysis revealed a significantly lower prevalence of dyslipidemia in both MS (SPR 0.45, 95% CI 0.18-0.93) and NMOSD (SPR 0.16, 95% CI 0.004-0.89) compared with the general population. However, dyslipidemia remained the strongest predictor of cardiovascular events in MS (p < 0.001). In NMOSD, despite a hypertension prevalence comparable to the general population (SPR 0.92), patients had significantly higher usage of angiotensin II receptor blockers (35.3% vs. 12.8%, p = 0.041) and direct oral anticoagulants (11.8% vs. 0%, p = 0.016), coinciding with universal corticosteroid use (100%).
CONCLUSION: Taiwanese MS and NMOSD patients exhibit distinct cardiovascular phenotypes. MS is characterized by a "lipid paradox" where dyslipidemia, though less prevalent, serves as a high-potency risk trigger. In NMOSD, cardiovascular risk is treatment-related and masked by high medication burden. Comprehensive risk assessment must prioritize these specific metabolic and iatrogenic factors.